MARKET

EIGR

EIGR

Eiger
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.62
+0.07
+0.66%
Opening 14:09 01/22 EST
OPEN
10.46
PREV CLOSE
10.55
HIGH
10.79
LOW
10.43
VOLUME
113.63K
TURNOVER
--
52 WEEK HIGH
14.79
52 WEEK LOW
4.550
MARKET CAP
345.49M
P/E (TTM)
-4.3482
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Global Hypertensive Heart Disease Market 2021 – Industry Analysis, Size, Share, Strategies and Forecast to 2027
Jan 21, 2021 (Heraldkeepers) -- Global Hypertensive Heart Disease Industry Hypertensive heart diseases refer to heart failure, CAD (coronary artery disease),...
Heraldkeepers · 1d ago
Wedbush Reiterates a Buy Rating on Eiger Biopharmaceuticals (EIGR)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Eiger Biopharmaceuticals (EIGR), with a price target of $22.00. The
SmarterAnalyst · 3d ago
Ameriprise Financial Reports In 13G Filing A Passive Stake Of 12.06% In Eiger BioPharmaceuticals
-SEC Filing
SEC Filing · 01/11 16:55
Eiger targets Zokinvy EMA approval and late-stage trial initiation for Lambda in 2021
Eiger BioPharmaceuticals ([[EIGR]] -5.6%) expects EMA approval for its Hutchinson-Gilford progeria syndrome treatment Zokinvy, and plans to start its Phase 3 HDV LIMT-2 ((Lambda)) trial, both in the second half of
Seekingalpha · 01/07 17:00
Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans
, /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today updated on progress acr...
PR Newswire - PRF · 01/07 13:00
Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans
PR Newswire · 01/07 13:00
A New Gene-Editing Technique May Be Able to Help Children Who Prematurely Age
Scientists report that a novel gene-editing technology was able to correct the genetic mutation that causes progeria in lab mice and spare them its effects.
Barrons.com · 01/06 16:00
Citing uncertainty, Baird stays neutral on Biotech for 2021
Heading into 2021, Baird keeps a neutral view on Biotechnology despite higher expectations after the sector with a 26% gain in the iShares Nasdaq Biotechnology ETF (IBB) outperformed in 2020
Seekingalpha · 01/04 21:40
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EIGR. Analyze the recent business situations of Eiger through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EIGR stock price target is 31.67 with a high estimate of 49.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 135
Institutional Holdings: 25.09M
% Owned: 77.11%
Shares Outstanding: 32.53M
TypeInstitutionsShares
Increased
43
2.63M
New
26
1.51M
Decreased
25
1.30M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.76%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Independent Director
Thomas Dietz
President/Chief Executive Officer/Director
David Cory
Chief Financial Officer
Sriram Ryali
Executive Vice President
Eldon Mayer
Chief Compliance Officer/General Counsel/Secretary
Stephana Patton
Other
James Shaffer
Director
David Apelian
Independent Director
Jeffrey Glenn
Independent Director
Evan Loh
Independent Director
Christine Murray
Independent Director
Amit Sachdev
Director
Patrick Y. Yang
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EIGR
Eiger BioPharmaceuticals Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing drugs for serious diseases. Its product candidate pipeline includes programs, including Lonafarnib (LNF), Peginterferon Lambda (lambda), LNF in Progeria and Progeroid Laminopathies (PL), Avexitide. LNF is an orally bioavailable, farnesylation inhibitor in Phase-III clinical trials for Hepatitis Delta Virus (HDV) infection. Lambda is a late-stage, type III interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. It is also developing lonafarnib for treatment of Progeria and Progeroid Laminopathies. Avexitide is a peptide that it is being developed as a treatment for Post-Bariatric Hypoglycemia (PBH). Avexitide is also being developed for Congenital Hyperinsulinism (CHI).
More

Webull offers kinds of Eiger Biopharmaceuticals Inc stock information, including NASDAQ:EIGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIGR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EIGR stock methods without spending real money on the virtual paper trading platform.